In a recently released update of guidelines issued jointly by the American College of Cardiology (ACC), the American Heart Association (AHA), and the Society of Cardiovascular Angiography and Interventions (SCAI), the short-acting anticoagulant bivalirudin received an upgraded recommendation as a measure that may improve the safety of angioplasty with stenting in people who are suffering a major heart attack. Bivalirudin, which belongs to a class of drugs known as direct thrombin inhibitors, is marketed as Angiomax.

CRF News and Events
CRF News and Events |
|
|
|
|
More Articles...
|
|
|
«StartPrev1234567NextEnd» |
|
| Page 4 of 7 |
About CRF
Upcoming Events
|
Transcatheter Cardiovascular Therapeutics |
|
Pulse of the City Gala |
|
Medical Innovation Summit |
CRF Websites
TCTMD.com
The source for interventional cardiovascular news & education.
HeartHealthyWomen.org
The online source for information on heart disease in women.